Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
Date:2/26/2013

termined based on complex assumptions that may vary as a result of conditions outside of our control, and because we believe exclusion of these expenses facilitates comparison of Auxilium's operating results to those of our peer group companies. 

Net interest expense for 2013 excludes approximately $12 million of non-cash interest expense related to the convertible senior notes due 2018 because we believe the exclusion facilitates investors' ability to understand the effect of our debt service obligations on our liquidity as well as comparison of Auxilium's operating results to those of our peer group companies.

See Table 5 attached for a summary of guidance.

See Table 6 for reconciliation of forecasted non-GAAP results to the most directly comparable GAAP measure.

Conference CallAuxilium will hold a conference call today, February 26, 2013 at 10:00 a.m. ET, to discuss fourth quarter and full year 2012 results, as well as the financial guidance it has provided for 2013. The presentation slides to be used during the call will be available on the "For Investors" section of the Company's web site under the "Presentations" tab at 10:00 a.m. E.T.  A question and answer session will follow the presentation.  The conference call and the presentation slides will be simultaneously web cast on the "For Investors" section of the Company's web site under the "Events" tab.  The conference call will be archived for future review until May 26, 2013.Conference call details:Date:Tuesday, February 26, 2013Time: 

10:00 a.m. ETDial-in (U.S.):866-510-0705Dial-in (International):617-597-5363Web cast:

http://www.auxilium.comPasscode:AUXILIUMTo access an audio replay of the call:Access number (U.S.): 

888-286-8010 Access number (International): 

617-801-6888Replay Passcode #: 

92145279About AuxiliumAuxilium is a specialty biopharmaceutical company with a focus on developing an
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Auxilium Announces Appointments to Enhance Leadership Team
2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
4. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
6. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
7. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
10. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
11. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Whitehouse Laboratories is excited to announce ... PTI Inspection Systems that will enable it ... art leak testing method development and validation programs using ... As part of this agreement, Whitehouse Labs has taken ... Instrument developed and manufactured by PTI. The HVLD ...
(Date:8/27/2014)... Rhythm, a biopharmaceutical company developing peptide therapeutics that address ... disorders, announced today that it has filed a registration ... Exchange Commission (SEC) relating to the proposed initial public ... of shares to be offered and the price range ... Citigroup and Cowen and Company will act as ...
(Date:8/27/2014)... DENVER , Aug. 27, 2014   MSC ... and patient safety, today announced the appointment of ... With 28 years of experience preparing companies ... in 2013 as Executive Vice President of Corporate Development ... healthcare performance improvement business , as well as corporate ...
(Date:8/27/2014)... 27, 2014 Reportlinker.com announces that a ... catalogue: Global Chelating Agents Market 2014-2018 ... About Chelating Agent A chelating agent is a ... metal ions, thereby forming a metal-ion complex. It ... on chemical processes, formulations, and the environment by ...
Breaking Biology Technology:Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2MSC names Mary Beth Loesch President and CEO 2Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4
... Therapeutics Corporation,announced today that it has entered into ... SHPGY, TSX: SHQ), to jointly develop AT-1001,Alba,s lead ... Shire will receive rights to commercialize all forms ... Alba will retain all rights,to commercialize AT-1001 in ...
... Dec. 14 Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ... promoted B. Lynne Parshall, J.D. to Chief Operating ... Chief Financial,Officer, and is a Director of the ... reflects the scope,of Lynne,s responsibilities at Isis," commented ...
... PHILADELPHIA, Dec. 14 FMC Corporation (NYSE:,FMC) ... announced the companies,have entered into a worldwide ... a novel capsule technology developed by FMC. ... strengthen,the product life-cycle management of Pronova BioPharma,s ...
Cached Biology Technology:Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001 2Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001 3Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 2Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 3FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 2FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 3FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 4
(Date:8/28/2014)... MARC (Maximizing Access to Research Careers) Program has ... College of Sports Medicine,s Conference on Integrative Physiology ... Florida. These awards are meant to promote ... from underrepresented groups into the mainstream of the ... of young scientists at the American College of ...
(Date:8/28/2014)... German . Cars, ... help of sophisticated assembly lines. Mobile assembly carriers, on to ... these assembly lines. In the case of a car body, ... in a precise spatial and chronological sequence, resulting in a ... creation of such an assembly line at molecular level has ...
(Date:8/28/2014)... assigned a number of 435-million-year-old fossils to a ... in shallow marine habitats and were far less ... , Before they sank to the bottom ... some 435 million years ago, these arthropods preyed ... although they were not exactly inconspicuous, possessing a ...
Breaking Biology News(10 mins):Nanoscale assembly line 2Nanoscale assembly line 3Paleontology: Oldest representative of a weird arthropod group 2
... When you think you see a face in the clouds or ... be upside down. It turns out the answer to this ... to. Using tests of visual perception and functional magnetic resonance ... Ontario,s world-renowned Centre for Brain & Mind recently measured activity in ...
... Mention vitamin D-fortified foods and most people think ... vitamin since the 1930s. A new episode in the ... series says that vitamin D-fortified bread could join milk ... is difficult to get naturally in foods. ...
... Minnesota,s College of Biological Sciences, has been awarded a five-year, ... direct a large-scale research effort to study a human antiviral ... The goal of the study will be to produce ... how it interacts with other proteins in human cells and ...
Cached Biology News:U of M scientist gets 5-year, $10 million grant to direct innovative HIV research program 2
... Recognizes an epitope located in ... isotype IV. No reactivity with ... ascites fluid synthetic peptide corresponding ... β-tubulin isotype IV, conjugated to ...
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
... catalyzes the joining of two strands of ... groups of adjacent nucleotides in either a ... has also been shown to catalyze the ... or RNA strand in a duplex molecule ...
Biology Products: